| Literature DB >> 24114606 |
S Portaro1, D Parisi2, A Polizzi3, M Ruggieri4, F Andreetta5, P Bernasconi5, A Toscano2, C Rodolico6.
Abstract
Lambert-Eaton myasthenic syndrome is a neuromuscular junction disorder characterized by proximal limb muscle weakness, fatigability, decreased deep-tendon reflexes, and autonomic symptoms. There are 2 forms of Lambert-Eaton myasthenic syndrome: one most frequently associated with small-cell lung cancer (P-Lambert-Eaton myasthenic syndrome) and the other that is a pure autoimmune form (NP-Lambert-Eaton myasthenic syndrome). Lambert-Eaton myasthenic syndrome is a very rare disorder in children younger than age 12 years. Herein, we report a 25-year-old man with NP-Lambert-Eaton myasthenic syndrome, which onset was at the age of 10 years. To date, this is the most long-term follow-up of NP-Lambert-Eaton myasthenic syndrome in childhood. In our patient, the only symptomatic treatment with 3,4-diaminopyridine phosphate has been sufficient to guarantee him a good quality of life. Our data remind physicians to keep in mind the diagnosis of Lambert-Eaton myasthenic syndrome in children with a proximal myopathic pattern and they confirm the specificity of compound muscle action potential incremental pattern after brief maximal effort in Lambert-Eaton myasthenic syndrome.Entities:
Keywords: 3,4-diaminopyridine phosphate; Lambert-Eaton syndrome; anti-voltage-gated calcium channel antibodies; proximal muscle weakness
Mesh:
Year: 2013 PMID: 24114606 DOI: 10.1177/0883073813499970
Source DB: PubMed Journal: J Child Neurol ISSN: 0883-0738 Impact factor: 1.987